| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199211263272203 |
| P698 | PubMed publication ID | 1435882 |
| P50 | author | Anders Björklund | Q5577627 |
| P2093 | author name string | J W Langston | |
| P Brundin | |||
| O Lindvall | |||
| B Snow | |||
| H Widner | |||
| S Rehncrona | |||
| B Gustavii | |||
| J Tetrud | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| parkinsonian syndrome | Q1531991 | ||
| P304 | page(s) | 1556-63 | |
| P577 | publication date | 1992-11-26 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) | |
| P478 | volume | 327 |
| Q48858846 | A Critical Evaluation of the Methodological Obstacles to Translating Cell-Based Research Into an Effective Treatment for People With Parkinson's Disease |
| Q38784743 | A Subpopulation of Dopaminergic Neurons Coexpresses Serotonin in Ventral Mesencephalic Cultures But Not After Intrastriatal Transplantation in a Rat Model of Parkinson's Disease |
| Q72332220 | A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions |
| Q45887965 | A method to codetect introduced genes and their products in gene therapy protocols |
| Q60064762 | A revived opportunity for fetal research |
| Q33791830 | AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. |
| Q38191589 | Adult subventricular zone neural stem cells as a potential source of dopaminergic replacement neurons |
| Q92131901 | Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients |
| Q72033014 | Allogeneic grafts of fetal dopamine neurons: immunological reactions following active and adoptive immunizations |
| Q35575249 | Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease |
| Q48171351 | An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. |
| Q44535345 | Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells |
| Q59574368 | Basic neural transplantation techniques. I. Dissociated cell suspension grafts of embryonic ventral mesencephalon in the adult rat brain |
| Q72625393 | Behavioral assessment of the ability of intracerebral embryonic neural tissue grafts to ameliorate the effects of brain damage in marmosets |
| Q40495978 | Behavioural consequences of neural transplantation |
| Q41588794 | Benefits and risks of hosting animal cells in the human brain. |
| Q64814787 | Bilateral intracaudate cografting of fetal ventral mesencephalon and striatum in advanced Parkinson's disease |
| Q34476794 | Book Review: Gene Therapy with Herpes Simplex Virus Vectors: Progress and Prospects for Clinical Neuroscience |
| Q37796021 | Brain imaging after neural transplantation |
| Q38829948 | Brain repair and reprogramming: the route to clinical translation. |
| Q41485090 | Brain repair. |
| Q26776041 | Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies |
| Q38079793 | Cell Therapy for Parkinson's Disease: What Next? |
| Q48894191 | Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells |
| Q37921767 | Cell replacement therapy for Parkinson's disease: how close are we to the clinic? |
| Q34327144 | Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease |
| Q33212017 | Cell therapy in Parkinson's disease |
| Q44628139 | Cell therapy in Parkinson's disease - stop or go? |
| Q35736662 | Cell-based therapies for Parkinson disease—past insights and future potential |
| Q57169781 | Cell-based therapy for Parkinson's disease: A journey through decades toward the light side of the Force |
| Q72273618 | Cell-binding peptides conjugated to poly(ethylene glycol) promote neural cell aggregation |
| Q41417768 | Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system |
| Q36438745 | Cellular imaging in drug discovery |
| Q28206557 | Cellular replacement therapy for Parkinson's disease--where we are today? |
| Q40909193 | Cerebral transplantation for Parkinson's disease: current progress and future prospects |
| Q45756120 | Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in a Rat Model of Parkinson’s Disease |
| Q34953242 | Clinical neurotransplantation: core assessment protocol rather than sham surgery as control |
| Q34120746 | Clinical observations after neural transplantation in Parkinson's disease |
| Q64860977 | Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale |
| Q64787878 | Co-grafts of muscle cells and mesencephalic tissue into hemiparkinsonian rats: behavioral and histochemical effects |
| Q42279276 | Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report |
| Q41264952 | Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders |
| Q33704308 | Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). |
| Q36370618 | Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease |
| Q33809293 | Development of fetal neural transplantation as a treatment for Parkinson's disease |
| Q48181098 | Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation |
| Q35732928 | Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. |
| Q40800989 | Discordant xenografts: different outcome after mouse and rat neural tissue transplantation to guinea-pigs |
| Q35648129 | Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials |
| Q34480963 | Dopamine release from transplanted neural stem cells in Parkinsonian rat striatum in vivo |
| Q70911547 | Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon |
| Q33565361 | Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. |
| Q42477973 | Dopaminergic reinnervation of the globus pallidus by fetal nigral grafts in the rodent model of Parkinson's disease |
| Q48590785 | Dyskinesias following neural transplantation in Parkinson's disease |
| Q38182651 | Dyskinesias in Parkinson's disease: views from positron emission tomography studies |
| Q49080218 | Effects of brain-derived neurotrophic factor on neuronal structure of dopaminergic neurons in dissociated cultures of human fetal mesencephalon |
| Q36273378 | Embryonic stem cells as a cell source for treating Parkinson's disease |
| Q42503701 | Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants. |
| Q45288976 | Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. Network of European CNS Transplantation and Restoration (NECTAR). |
| Q33806616 | Ethical issues in neurografting of human embryonic cells |
| Q33581952 | Ethics of fetal tissue transplantation |
| Q74783450 | Fetal Tissue Research: The Cutting Edge? |
| Q38067203 | Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease |
| Q48715606 | Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants |
| Q39116027 | Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease |
| Q41367101 | Fetal nigral transplantation as a therapy for Parkinson's disease |
| Q34710384 | Fetal tissue transplantation and abortion decisions: a survey of urban women |
| Q34458450 | Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results |
| Q48872737 | Fetal ventral mesencephalon of human and rat origin maintained in vitro and transplanted to 6-hydroxydopamine-lesioned rats gives rise to grafts rich in dopaminergic neurons. |
| Q44601852 | First human ventral mesencephalon and striatum cografting in a parkinson patient |
| Q26765499 | Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia |
| Q45864156 | GENETICALLY MODIFIED PRIMARY ASTROCYTES AS CELLULAR VEHICLES FOR GENE THERAPY IN THE BRAIN. |
| Q34179305 | Gene delivery and gene therapy with herpes simplex virus-based vectors |
| Q38166648 | Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications |
| Q24680275 | Gene therapy in clinical medicine |
| Q34455675 | Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells |
| Q73387823 | Glial cell line—derived neurotrophic factor—supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage |
| Q41033079 | Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats |
| Q53524831 | Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease |
| Q35216671 | Herpes simplex virus vectors for Parkinson's disease |
| Q74163540 | Homotransplant of pelvic ganglion into bladder wall in adult rats |
| Q39282792 | Human fetal pancreatic islet-like structures as source material to treat type 1 diabetes |
| Q35648168 | Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges |
| Q41386986 | Hypersusceptibility to chemicals: risk factors for neurological disease? |
| Q43693354 | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease |
| Q34053847 | Idiopathic Parkinson's disease: epidemiology, diagnosis and management. |
| Q36718204 | Imaging the head: functional imaging |
| Q41607294 | Implications of neurological rehabilitation for advancing intracerebral transplantation |
| Q34120728 | Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease |
| Q45298655 | In vivo magnetic resonance spectroscopy of human fetal neural transplants |
| Q45222543 | Individual human serum differs in the amount of antibodies with affinity for pig fetal ventral mesencephalic cells and the ability to lyse these cells by complement activation |
| Q35073054 | Insulin-like growth factors act synergistically with basic fibroblast growth factor and nerve growth factor to promote chromaffin cell proliferation. |
| Q34999790 | Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. |
| Q30830441 | Long-term MRI cell tracking after intraventricular delivery in a patient with global cerebral ischemia and prospects for magnetic navigation of stem cells within the CSF |
| Q26773485 | Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease |
| Q35131249 | Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain |
| Q36883776 | Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease |
| Q34409502 | Multiple system atrophy: current and future approaches to management |
| Q77314451 | Nerve growth factor delivery systems |
| Q38383700 | Neural Stem Cells Derived From Human Parthenogenetic Stem Cells Engraft and Promote Recovery in a Nonhuman Primate Model of Parkinsons Disease |
| Q71796889 | Neural Transplantation |
| Q64946579 | Neural Transplantation in Parkinson's Disease |
| Q37796027 | Neural grafting in Parkinson's disease Problems and possibilities |
| Q41045387 | Neural stem and progenitor cells: a strategy for gene therapy and brain repair. |
| Q40779644 | Neural stem cells for CNS transplantation |
| Q40779636 | Neural transplantation for neurodegenerative diseases: past, present, and future |
| Q36560830 | Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature |
| Q48316816 | Neurobiology. Better cells for brain repair |
| Q36045259 | Neurodegeneration and neuroprotection in Parkinson disease |
| Q50859562 | Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease |
| Q30580687 | New developments in the surgery for Parkinson's disease |
| Q34120750 | Non-invasive in vivo imaging of transplant function. |
| Q64869820 | Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease |
| Q46340686 | Outcome Following Intrastriatal Fetal Mesencephalic Grafts for Parkinson's Patients Is Directly Related to the Volume of Grafted Tissue |
| Q72250208 | Parkinson's disease |
| Q72320618 | Parkinson's disease |
| Q48333572 | Parkinson's disease. Fetal implants put to the test |
| Q99238086 | Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities |
| Q48422380 | Porcine fetal ventral mesencephalic cells are targets for primed xenoreactive human T cells |
| Q41718477 | Positron Emission Tomography Studies in Movement Disorders |
| Q36045402 | Positron emission tomography imaging of transplant function. |
| Q41107692 | Potential of immortalized neural progenitor cells to replace lost adult central nervous system neurons |
| Q48693253 | Preliminary Voice and Speech Analysis Following Fetal Dopamine Transplants in 5 Individuals With Parkinson Disease |
| Q42545361 | Proceedings: cell therapies for Parkinson's disease from discovery to clinic |
| Q44369863 | Production of dopaminergic neurons for cell therapy in the treatment of Parkinson's disease |
| Q45297193 | Prospectives for cell and gene therapy in Huntington's disease |
| Q40429860 | Radical directions in Parkinson's disease |
| Q48586516 | Rat Intrastriatal Neural Allografts Challenged with Skin Allografts at Different Time Points |
| Q34455968 | Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase |
| Q35119398 | Reconstructive neurosurgery for Parkinson’s disease: a systematic review and preliminary meta-analysis |
| Q35028568 | Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism |
| Q67215797 | Regression of parkinsonian fetal ventral mesencephalon grafts upon withdrawal of cyclosporine A immunosuppression. The CPH Neural Transplantation Group. |
| Q71378200 | Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic grafts |
| Q37693379 | Replacing Dopamine Neurons in Parkinson's Disease: How did it happen? |
| Q46109283 | Restorative Strategies in Movement Disorders: the Contribution of Imaging |
| Q33542732 | Review of allo- and xenogeneic neural grafts in neurodegenerative disorders. Neural Tissue Transplantation Team(NETTLU). |
| Q40728105 | Scientific and ethical concerns in neural fetal tissue transplantation |
| Q38105849 | Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain |
| Q48095855 | Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. |
| Q43989261 | Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts in mice lacking CD40L. |
| Q64786689 | Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease |
| Q70794481 | Spinal cord transplants: a future treatment for spinal injury? |
| Q35236822 | Stem cell therapy for Parkinson's disease. |
| Q41008595 | Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats |
| Q34371507 | Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo |
| Q45193147 | Syngeneic central nervous system transplantation of genetically transduced mature, adult astrocytes |
| Q40493894 | The History, Theory, and Present Status of Brain Transplantation |
| Q40911146 | The Use of Nonneuronal Cells for Gene Delivery |
| Q53629088 | The brain and the I: neurodevelopment and personal identity |
| Q48654409 | The effect of nigral implantation on sensitization to dopamine agonists in 6-hydroxydopamine-lesioned rats |
| Q48654554 | The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain. II. Correlation between positron emission tomography and reaching behaviour. |
| Q48715536 | The effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells |
| Q38004257 | The immunological challenges of cell transplantation for the treatment of Parkinson's disease. |
| Q34120740 | The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies |
| Q36696227 | The role of positron emission tomography in the assessment of human neurotransplantation |
| Q48372783 | The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies |
| Q37631734 | Therapeutic Potential of Induced Neural Stem Cells for Parkinson's Disease. |
| Q37135427 | Therapeutic strategies for Parkinson's disease: the ancient meets the future--traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells |
| Q41652122 | Transplantation in Parkinson's Disease |
| Q34075118 | Transplantation therapy for Parkinson's disease |
| Q27024152 | Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? |
| Q72844311 | Treatment of Parkinson's disease |
| Q41573779 | Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques |
| Q31118947 | Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. |
| Q92775462 | Uses for humanised mouse models in precision medicine for neurodegenerative disease |
| Q33816851 | Viral vectors in the treatment of Parkinson's disease |
Search more.